Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Clearmind CMND-100 Phase IIa AUD Enrollment

Analysis based on 16 articles · First reported Sep 01, 2026 · Last updated Sep 11, 2026

Sentiment
10
Attention
2
Articles
16
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The news is a modest positive catalyst for Clearmind Medicine, signaling clinical progress in its lead CMND-100 program and potentially supporting the Nasdaq-listed microcap's share price on a sentiment basis. Broader market impact is negligible given the company's small size and the early-stage nature of the trial, with effects largely confined to the biotechnology and psychedelic-therapeutics sector.

biotechnology pharmaceuticals

Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biopharmaceutical company developing non-hallucinogenic psychedelic-derived neuroplastogens, announced the initiation of Phase IIa, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). On September 1, 2026, the company reported that six patients had been enrolled to date, with three participants at Tel Aviv Sourasky Medical Center (TASMC) and three at Hadassah Medical Center in Jerusalem, initiating the first multiple-dose treatment phase of Part C following successful completion of the trial's initial safety part in healthy volunteers. On September 11, 2026, Clearmind announced the enrollment of the first two patients with AUD at Hadassah Medical Center in Jerusalem, marking the first time CMND-100 was administered to a patient with AUD. CEO Adi Zuloff-Shani stated that the enrollment trajectory continues to build positively and that treating the first AUD patients with CMND-100 represents a major step forward. The trial is designed to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with moderate-to-severe AUD. An independent Data and Safety Monitoring Board previously reviewed Part A data and recommended advancing to subsequent parts of the study. Clearmind's intellectual portfolio consists of nineteen patent families, including 32 granted patents.

85 Clearmind Medicine initiated Phase IIa trial
70 Clearmind Medicine reported positive safety results
stock
Clearmind Medicine is the sponsor and central actor of the event, advancing its lead candidate CMND-100 into Phase IIa and enrolling the first AUD patients. The clinical progress is a positive milestone that could support investor sentiment and the company's Nasdaq-listed shares.
Importance 100.0 Sentiment 25.0
per
Adi Zuloff-Shani, Chief Executive Officer of Clearmind, publicly commented on the enrollment milestone, framing it as a major step forward for the program. Her statements help shape investor perception of the company's clinical momentum.
Importance 40.0 Sentiment 10.0
cnt
Israel hosts both clinical trial sites, Hadassah Medical Center and Tel Aviv Sourasky Medical Center, where CMND-100 is being tested. The event has no material effect on the country's markets.
Importance 25.0 Sentiment 0.0
exch
Nasdaq is the exchange where Clearmind Medicine shares (CMND) are listed and traded. The event may influence trading activity in the stock but has no material impact on the exchange itself.
Importance 20.0 Sentiment 0.0
Israel related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.